AGP Executive Report
Last update: 9 hours agoRegulatory Win (India): Leiutis Pharma says India’s CDSCO has approved its partner Zenara Pharma to manufacture and market a proprietary synthetic CBD oral solution (150 mg/mL) for mild-to-moderate anxiety disorders, to be prescribed only by psychiatrists and backed by Phase III results plus a planned Phase IV. Policy & Access (US): A federal DEA rescheduling hearing on the Trump administration’s cannabis proposal has wrapped, with a judge setting post-hearing brief deadlines (due Aug. 17) before a recommendation. Clinical Reality Check: A JAMA review notes medical cannabis may help some people with chronic non-cancer pain, insomnia, and anxiety, but much of the support comes from small studies, and risks like cannabis use disorder and high-potency psychotic symptoms remain concerns. Patient-Provider Gap (Cancer): A VCU survey finds cancer survivors and care providers broadly align on cannabis use, but differ on risk awareness and how comfortable they are discussing it. Product/Use (Sleep): A small study on cannabis-infused tea reports improved happiness and sleep quality, with the highest dose (7%) showing the strongest results. Community (NJ): Dank Poet in Washington, NJ is hosting a blood drive on July 29 to support local patients needing ongoing blood supply.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
